Targeting Fatty Acid Metabolism to Fight Brain Cancer (GBM)
Official title: Targeting Fatty Acid Oxidation with Etomoxir for the Treatment of Recurrent Glioblastoma
Funded at Numiera Therapeutics INC · NIH-11314195 · Data updated 2026-11-12
A new treatment approach uses a repurposed drug to cut off the energy supply of glioblastoma tumors in the brain.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Numiera Therapeutics INC NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,204,195 |
| NIH project number | 1R44CA310352-01 |
| Project ID | NIH-11314195 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with recurrent glioblastoma or related brain tumors who may be eligible for future clinical testing of etomoxir.
✕Less likely to help
Patients with non-GBM brain tumors or significant comorbidities may not benefit and could be at risk from any new therapy.
What this research studies
This project explores using etomoxir to interrupt the fatty acid energy pathway that glioblastoma cells rely on. Researchers will test the drug in preclinical models and move toward human studies to see if it can slow tumor growth and improve survival. The goal is to translate a known heart-drug into a potential brain cancer therapy, with careful attention to safety and effectiveness. If successful, this work could open a new avenue for patients whose GBM has recurred and limited options.
Why it matters
Potential benefit: If successful, patients with recurrent glioblastoma could have a new treatment option that slows disease progression and extends survival.
How similar studies have gone: Prior studies in mouse models and patient-derived GBM samples showed survival benefits, supporting progression toward clinical testing.
Where this research is happening
-
Numiera Therapeutics INC
Denver, United States Active
Researchers
- Principal investigator: Stoll, Elizabeth — Numiera Therapeutics INC
- Study coordinator: Stoll, Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Giving immune checkpoint therapy before surgery for recurrent glioblastoma
This research gives an immune checkpoint drug before surgery to people with recurrent glioblastoma to help the immune system attack the tumor.
-
Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
-
Using immune therapy before surgery for recurrent glioblastoma
This study is looking at how giving a special immune therapy before surgery can help patients with recurrent glioblastoma fight their tumors better, and it will compare the results to the usual treatments given after surgery.
-
Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.